Qfol400 mcg

Qfol is the naturally occurring, biologically active form of folate (vitamin B9). Unlike synthetic folic acid, it does not require enzymatic reduction by dihydrofolate reductase or the MTHFR enzyme before it can be used by the body, so it can be absorbed and utilized directly.

Established / commonly used indications

• Prevention and treatment of folate deficiency, including deficiency related to poor dietary intake, malabsorption, pregnancy, or increased physiological demand.
• Nutritional supplementation before and during pregnancy to support normal fetal neural tube development and reduce the risk of neural tube defects, as part of routine prenatal care.
• Alternative to synthetic folic acid in individuals with reduced capacity to convert folic acid to its active form, such as those with common MTHFR gene variants (e.g., C677T), or with folate malabsorption.

Adjunct / specialist uses (require combination therapy or physician supervision)

• As adjunctive nutritional support alongside an existing antidepressant in adults with major depressive disorder who have suboptimal folate status — used in addition to, not instead of, prescribed antidepressant therapy.
• As adjunctive support in patients with hyperhomocysteinemia and schizophrenia already stabilized on antipsychotic therapy.
• Nutritional support of folate status in patients on long-term dialysis or on medications that interfere with folate metabolism (e.g., certain antiepileptics, methotrexate), under medical supervision.

Evidence for superiority of Qfol over standard folic acid in the general population (outside genetic-variant or malabsorption contexts) is limited, and such use should be viewed as a nutritional/supportive measure rather than a proven outcome-altering therapy.

6s-5-Methyltetrahydrofolate [Bio-Active Folate] is typically supplied as an oral capsule or tablet containing L-methylfolate (as a calcium or glucosamine salt) in strengths such as 400 mcg and 1000 mcg for general dietary supplementation, and higher prescription strengths (e.g., 7.5 mg and 15 mg) in certain medical-food products intended for adjunctive psychiatric use. Each product's label should be checked for the exact strength and salt form.

Qfol (also known as L-methylfolate or levomefolate) is the predominant, biologically active circulating form of folate in the human body. It functions as the direct methyl donor required for the conversion of homocysteine to methionine and supports one-carbon metabolism, DNA/RNA synthesis, and cell division. Because it bypasses the enzymatic reduction steps needed to activate synthetic folic acid, it is marketed as a folate source suitable for individuals who convert folic acid less efficiently.

Vitamins and minerals — active folate (vitamin B9) derivative / medical food and dietary supplement.

6s-5-Methyltetrahydrofolate [Bio-Active Folate] is absorbed intact in the small intestine via folate transporters (reduced folate carrier and proton-coupled folate transporter) without requiring conversion by dihydrofolate reductase or 5,10-methylenetetrahydrofolate reductase (MTHFR). It circulates in plasma and enters cells, where it donates a methyl group in the vitamin B12-dependent conversion of homocysteine to methionine, catalyzed by methionine synthase. This reaction regenerates tetrahydrofolate, which is required for purine and thymidylate synthesis (essential for DNA replication and cell division) and for the methylation cycle that produces S-adenosylmethionine, an important methyl donor for numerous biological reactions, including neurotransmitter synthesis.

Take Qfol by mouth, with or without food, at approximately the same time each day. Swallow capsules/tablets whole with a glass of water unless the product labeling states otherwise. Do not increase the dose beyond what is prescribed or labeled without consulting a physician.

Qfol has the following clinically relevant interactions:

• Antiepileptic drugs (e.g., phenytoin, carbamazepine, valproate): folate can lower plasma anticonvulsant levels in some patients, and these drugs can also reduce folate absorption/levels; monitor seizure control and folate status during concurrent use.
• Methotrexate and other dihydrofolate reductase inhibitors: folate supplementation may reduce the therapeutic (antifolate) effect of methotrexate when methotrexate is used for its cytotoxic or immunosuppressive action; coordinate timing and dose with the prescribing physician.
• Fluoxetine and other agents affecting folate transport: may reduce folate uptake/utilization; clinical significance is usually modest but should be considered in patients on combined therapy.
• Sulfasalazine and trimethoprim: can impair folate absorption or metabolism with long-term use.

Qfol is generally very well tolerated. Reported adverse effects are uncommon and include:

• Gastrointestinal: nausea, decreased appetite, bloating, flatulence, diarrhea.
• Hypersensitivity reactions: skin rash, pruritus, urticaria; rare severe allergic/anaphylactic reactions have been reported.
• Occasional reports of sleep disturbance, irritability, or vivid dreams, mainly at higher medical-food strengths used adjunctively.

Folate, including Qfol, is a recognized nutritional requirement during pregnancy and is widely used to support normal fetal development, but it should be used at the dose recommended by the treating physician rather than self-adjusted. As with any supplement in pregnancy, use only as advised, with the understanding that potential benefit is weighed against any theoretical risk of the specific product's dose or formulation. Qfol is excreted in breast milk; it is generally considered compatible with breastfeeding at recommended nutritional doses, but a physician should be consulted before use, particularly at higher (medical-food) strengths.

Masking of vitamin B12 deficiency: Folate supplementation, including with Qfol, can correct the megaloblastic anemia caused by vitamin B12 deficiency without correcting the underlying B12 deficiency. This can allow progressive and potentially irreversible neurological damage from B12 deficiency to continue unrecognized. Vitamin B12 status should be assessed before or during folate supplementation whenever clinically indicated, particularly in older adults, strict vegetarians/vegans, and patients with unexplained anemia or neurological symptoms; Qfol is not adequate treatment for pernicious anemia or confirmed B12 deficiency on its own.

Psychiatric caution: When used adjunctively in patients with major depressive disorder who are on antidepressants, caution is advised in individuals with a personal or family history of bipolar disorder, as antidepressant therapy (of which this is an adjunct) can be associated with precipitation of manic/hypomanic episodes.

General: Marketing claims of superiority over standard folic acid for general-population use should be interpreted cautiously, as high-quality outcome data supporting broad superiority (outside specific genetic-variant, malabsorption, or medical-food indications) remain limited. Excess folate is generally excreted and is not typically associated with toxicity at recommended doses.

Significant toxicity from Qfol overdose is unlikely given that excess folate is generally excreted in urine; however, very high intakes may theoretically worsen gastrointestinal upset or, in susceptible individuals, further mask vitamin B12 deficiency. If a substantial overdose is suspected or the patient develops concerning symptoms, seek immediate medical attention or contact a poison control center; do not attempt unsupervised home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Use with attention to concurrent vitamin B12 status, as age increases the risk of unrecognized B12 deficiency (see Precautions).

Renal impairment (including dialysis patients): May have increased folate requirements; Qfol is commonly used as nutritional support in this setting under physician supervision, though formal dose-adjustment data are limited.

Hepatic impairment: No well-established dose adjustment; use under medical guidance.

Pregnancy and lactation: See Pregnancy and Lactation section.

Pediatric use: See Pediatric Uses section.

Duration depends on the indication: correction of documented folate deficiency is typically continued for several weeks to a few months, guided by repeat folate levels; supplementation for pregnancy is generally continued through preconception, pregnancy, and lactation as advised by the physician; adjunctive use in depression or schizophrenia is continued for as long as the underlying condition and treatment plan require, under ongoing medical supervision. Long-term, low-dose nutritional supplementation may be continued indefinitely in individuals with an ongoing indication (e.g., malabsorption, MTHFR-related reduced conversion).

Vitamin/nutritional supplement; active (reduced) folate — vitamin B9 derivative.

6s-5-Methyltetrahydrofolate [Bio-Active Folate] acts as the immediately usable, biologically active form of folate, serving directly as the methyl donor for the vitamin B12-dependent conversion of homocysteine to methionine and for regeneration of tetrahydrofolate needed in DNA/RNA synthesis, bypassing the need for enzymatic activation of folic acid via dihydrofolate reductase and MTHFR.

Safety and efficacy of Qfol for indications beyond routine dietary intake have not been formally established in children. It may be used under pediatric medical supervision to address documented folate deficiency or specific metabolic/genetic indications, with dosing individualized by the treating physician based on age, weight, and clinical context; it is not intended for unsupervised pediatric self-medication.